



TR10 Cundt B (NE)
Cs
1-18-02
Docket No. 1878-4051

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): James BEASLEY et al.

Serial No.: 09/538,038

Group Art Unit: 1627

Filed: March 29, 2000

Examiner: Bennet Celsa

For: INSULIN AND IGF-1 RECEPTOR AGONIST AND ANTAGONISTS

**AMENDMENT AND RESPONSE TO OFFICE ACTION DATED
SEPTEMBER 27, 2001**

Commissioner for Patents
Washington, D.C. 20231

Sir:

This Amendment is submitted in response to the non-final Office Action dated September 27, 2001 requiring a substitute specification and substitute claims pursuant to 37 C.F.R. §1.125(a) and the Sequence Rules. Also filed herewith is 1) a substitute specification; 2) a marked copy of the substitute specification showing the sequence identifiers included; 3) substitute drawings; 4) marked copies of the substitute drawings showing the sequence identifiers included; 5) substitute claims; 6) marked copies of the substitute claims showing the sequence identifiers included; 7) a statement that the substitute specification, drawings, and claims contain no new matter. In accordance with 37 C.F.R. §1.7, this Amendment is timely filed on October 29, 2001. Applicants respectfully request entry and consideration of the following amendments in view of the accompanying remarks at the time of examination of the application.